Racura Oncology (ASX:RAC) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RAC Racura Oncology Ltd ASX:RAC
25 GF Score
Price A$2.05
View Full Analysis

What is Racura Oncology 3-Month Share Buyback Ratio?

Racura Oncology ASX:RAC 25 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates ASX:RAC with a GF Score™ of 25/100.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

ASX:RAC
25GF Score
Racura Oncology Ltd ASX:RAC
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Racura Oncology (ASX:RAC) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Racura Oncology and its competitors.
Is Racura Oncology's 3-Month Share Buyback Ratio too high?
Racura Oncology's current 3-Month Share Buyback Ratio is 0.00. Overall, Racura Oncology has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's 3-Month Share Buyback Ratio compare to VRTX and REGN?
Racura Oncology's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Racura Oncology and its competitors. Racura Oncology's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current 3-Month Share Buyback Ratio of 0.00. The current 3-Month Share Buyback Ratio is 0.00. Racura Oncology's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
25GF Score

Get the complete analysis for ASX:RAC

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.05
Price